Tuesday, August 12, 2008

Testing for cardiovascular risk

Health Research
Example: disease symptoms, health boards, etc..
Personalized search technology with Google
Testing for cardiovascular risk

In France, 1 in 3 people die from heart disease.
24 and 25 April next course will be held on the Heart. Organized by the French Federation of Cardiology in over 1100 cities, the most important manifestation of health prevention in France.

By changing the way we live very simply, we can act on our cardiovascular health, "0-5-30"
Habits of young people are worrying about their health tomorrow.

The Course of the Heart is a national event, very locally rooted, festive, family, with many physical activities available to all, and testing of cardiovascular risks.

Issues of Internet on this subject:
- How to detect a cardiac arrhythmia?
- How to diagnose heart failure in a man or a woman?
- Are there any free tests to detect heart problems in a teenager in France?

The most important manifestation of prevention public health: the Path of the Heart April 24-25 next

Scale operation in six major cities: a real village trail for the Heart
Brest, Lille, Nantes, Lyon, Bordeaux and Paris rally special. They each hold a "Village Heart and Health" open access. In addition to activities, visitors will benefit from screening tests (glucose, cholesterol, blood pressure check, measurement of tobacco abuse ...). Thanks to its partners and the generosity of its donors, the FFC provides access to a wide public, health diagnostics and qualitative completely free. For the third year set up his Paris Village Course of the Heart on the Plaza of City Hall (6000 attendees in 2009).

* Adolescents and young adults: a population of concern to cardiologists "Physical inactivity is progressing rapid in the youngest, who could become the heart of tomorrow," Professor Hervé Douard concerned, Vice-President of the FFC.
The FFC will reveal the results of a survey of young people before the Course of the Heart.

Friday, August 8, 2008

Experiences and expectations of patients with bipolar disorder type I

For the first time in France, patients with bipolar disorder type I were expressed as part of a study on their experience of illness and their expectations vis-à-vis health professionals, family members and society.

Conducted by IPSOS Health and led by a scientific committee of psychiatrists, this study provides insight into the issues of better therapeutic management of the disease, as well as a more successful integration of patients in society.

The study "bipolar I disorder: Experience and expectations of patients in 2009" was published on December 15 at a press conference organized by BMS and Otsuka, sponsors of the study.

- Dr Jean-Paul Chabannes, chief of psychiatry at CHS St. Egrève (Isère), presents and discusses the results of the study

- Dr Jean-Albert Meynard interview Annie Labbé, patient and president of the association ARGOS 2001 and illuminates the testimony of his experience as chief of psychiatry at the Centre Hospitalier Marius Lacroix, La Rochelle

Vis-à-vis the other, bipolar disorder type I are experienced as a cause of relationship problem: the feeling of rejection is felt for 38% of patients in their families and 44% in their circle of friends. 70% of them evoke a negative impact on working life, resulting in a perceived discrimination in the workplace, the employer's share (32%) but more importantly from colleagues (50%).

You can also download the brochure "Ideas true / false on bipolar disorder," published by the association and ARGOS 2001 Issues in Psychiatry, with support from Bristol-Myers Squibb and Otsuka.

Friday, August 1, 2008

Disease screening in France

The EFS system chooses the Novartis Diagnostics for screening blood products for HIV-1, hepatitis B and hepatitis C

The French Blood Establishment (EFS), the fifth largest blood collection organization in the world, chose the system of nucleic acid testing (NAT) Novartis Diagnostics to further reduce the risk of infection from blood products French and to prevent infections transmitted through transfusion. The system includes the first and only fully automated platform, Tigris, and testing for HIV-1, hepatitis B and hepatitis C Procleix ® Ultrio.

The adoption of the system Novartis Diagnostics offers the EFS solution fully automated blood test that meets the needs of its 14 sites, which cover all every year three million blood donations. Novartis has introduced its new systems in 14 sites in record time.

In preparation for the selection of Novartis Diagnostics as a sole supplier, the EFS has decided to opt for individual donor testing (IDT) in place and place of the method of "pooling" of blood donations ahead of tests NAT *. For EFS, the tests allow individual donors to provide the highest level of analytical sensitivity and eliminate the extra steps associated with the "pooling".

Novartis Diagnostics is a global leader in the field of high-sensitivity tests used to screen blood products in HIV, hepatitis B and C, and West Nile Virus. Previously, using the EFS system testing Novartis Diagnostics in a proportion that did not exceed 30% of its blood products.